What’s with the Imugene share price today?

Medical technicians wearing white medical coats conduct a test in a laboratory.Medical technicians wearing white medical coats conduct a test in a laboratory.

The Imugene Limited (ASX: IMU) share price lifted 4% today after the company released its March quarter report.

Imugene shares gained half a cent and were swapping hands at 13 cents in earlier trade but have since returned to their closing price yesterday of 12.5 cents.

The S&P/ASX All Ordinaries Index (ASX: XAO) has also lost a little ground in the late afternoon and is currently trading just 0.13% higher.

Let’s take a look at today’s report from the ASX biotech share.

Imugene share price goes green

Imugene is a clinical-stage immuno‐oncology company developing virotherapies that seek to activate the immune system of cancer patients to treat and kill off cancerous tumours.

There was nothing new in today’s report other than a few financial metrics. However, investors appear pleased with the company’s financial position and the progress it has made in its trials over the period.

Cancer trials

Key developments during the quarter include the first patients being dosed in the VAXINIA and Pembrolizumab combination study. VAXINIA is a cancer-killing virus.

Patients in the intravenous (IV) and intratumoral (IT) cohorts received their first dose of the immunotherapy.

Imugene aims to recruit up to 100 patients across several trial sites in the United States and Australia for this trial. It got approval to start trials in Australia during the quarter. The first hospital involved is Tasman Oncology Research in South Australia. Imugene is opening other sites now.

Imugene also began its multicenter Phase 1 MAST trial. The trial involves patients with metastatic or advanced solid tumours who have had at least two prior lines of existing standard cancer treatment.

Imugene’s preclinical laboratory and animal studies showed VAXINIA reduces the size of colon, lung, breast, ovarian and pancreatic cancer tumours.

New patent

Imugene also received a US patent until 2038 for its B-cell activating immunotherapy PD1-Vaxx.

PD1-Vaxx is in clinical development for non-small cell lung cancer (NSCLC). Imugene intends to run a clinical trial that combines PD1-Vaxx with the immune checkpoint inhibitor drug, atezolizumab.


In terms of the company’s financial position, Imugene had $151.5 million in cash or equivalents at the end of the quarter.

The company spent $10.6 million net cash on operating activities. Direct research and development and staff costs accounted for 83% of the expenditure.

Spreading the word on progress

Imugene presented at several conferences during the quarter, including the prestigious J.P. Morgan Healthcare Conference, which attracts thousands of global investors every year.

The company also presented its HER-Vaxx & CF33 platforms at the ASCO Gastrointestinal Cancers Symposium, which attracts thousands of oncologists, clinical researchers, and academics.

Imugene also gave a presentation at the NWR Healthcare Conference.

In addition, the biotech company announced positive imaging data for its oncolytic virotherapy candidate, CHECKvacc, last week.

Imugene share price snapshot

The Imugene share price is down 9.3% in 2023 so far.

Its peers in the S&P/ASX 200 Health Care Index (ASX: XHJ) have gone up 8.9%.

The post What’s with the Imugene share price today? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Imugene Limited right now?

Before you consider Imugene Limited, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of April 3 2023

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/a4g9lEB

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s